KRAS and neoplasm: Both KRAS‐mutant HPAF‐II and MIA PaCa‐2 (MIA) cell xenografts were refractory to AZD4573, with average tumor growth inhibition (TGI) rates of 58% and 27%, respectively, compared to 97% in an acute myelocytic leukemia (AML) cell xenograft model (MV‐4‐11) under the same treatment condition (Figure 1J).